AU2012213576B2 - Bifidobacterium bifidum strains for application in gastrointestinal diseases - Google Patents

Bifidobacterium bifidum strains for application in gastrointestinal diseases Download PDF

Info

Publication number
AU2012213576B2
AU2012213576B2 AU2012213576A AU2012213576A AU2012213576B2 AU 2012213576 B2 AU2012213576 B2 AU 2012213576B2 AU 2012213576 A AU2012213576 A AU 2012213576A AU 2012213576 A AU2012213576 A AU 2012213576A AU 2012213576 B2 AU2012213576 B2 AU 2012213576B2
Authority
AU
Australia
Prior art keywords
strain
probiotic formulation
powder
probiotic
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012213576A
Other languages
English (en)
Other versions
AU2012213576A1 (en
Inventor
Simone GUGLIELMETTI
Diego Mora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synformulas GmbH
Original Assignee
Synformulas GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synformulas GmbH filed Critical Synformulas GmbH
Publication of AU2012213576A1 publication Critical patent/AU2012213576A1/en
Application granted granted Critical
Publication of AU2012213576B2 publication Critical patent/AU2012213576B2/en
Assigned to DR. FISCHER GESUNDHEITSPRODUKTE GMBH reassignment DR. FISCHER GESUNDHEITSPRODUKTE GMBH Request for Assignment Assignors: NATURWOHL PHARMA GMBH
Assigned to SYNFORMULAS GMBH reassignment SYNFORMULAS GMBH Request for Assignment Assignors: DR. FISCHER GESUNDHEITSPRODUKTE GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2012213576A 2011-01-31 2012-01-27 Bifidobacterium bifidum strains for application in gastrointestinal diseases Active AU2012213576B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11000744.0A EP2481299B1 (en) 2011-01-31 2011-01-31 Bifidobacterium bifidum strains for application in gastrointestinal diseases
EP11000744.0 2011-01-31
PCT/EP2012/051369 WO2012104226A1 (en) 2011-01-31 2012-01-27 Bifidobacterium bifidum strains for application in gastrointestinal diseases

Publications (2)

Publication Number Publication Date
AU2012213576A1 AU2012213576A1 (en) 2013-08-08
AU2012213576B2 true AU2012213576B2 (en) 2015-07-23

Family

ID=43901563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012213576A Active AU2012213576B2 (en) 2011-01-31 2012-01-27 Bifidobacterium bifidum strains for application in gastrointestinal diseases

Country Status (15)

Country Link
US (1) US9408879B2 (enExample)
EP (1) EP2481299B1 (enExample)
JP (1) JP5956467B2 (enExample)
CN (1) CN103476273A (enExample)
AU (1) AU2012213576B2 (enExample)
BR (1) BR112013019258B1 (enExample)
CA (1) CA2825980C (enExample)
DK (1) DK2481299T3 (enExample)
ES (1) ES2610908T3 (enExample)
HR (1) HRP20161792T1 (enExample)
HU (1) HUE033189T2 (enExample)
PL (1) PL2481299T3 (enExample)
PT (1) PT2481299T (enExample)
RU (1) RU2603285C2 (enExample)
WO (1) WO2012104226A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN103266076B (zh) * 2013-06-04 2014-10-29 神舟太空产品高科技成果推广中心集团有限公司 太空诱变高效两歧双歧杆菌、其应用及其胶囊制剂的制备方法
CN104546945A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 两歧双歧杆菌在治疗或预防类风湿性关节炎或其相关疾病中的用途
ES2658310T3 (es) 2014-12-23 2018-03-09 4D Pharma Research Limited Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
CA2977901A1 (en) * 2015-03-09 2016-09-15 Bioimmunizer Sagl Anti-age composition comprising a combination of antioxidant agents in association with bifidobacteria and cell walls isolated from probiotics
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA55434B1 (fr) 2015-06-15 2022-02-28 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3307288T (pt) 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
TWI759266B (zh) 2015-06-15 2022-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物之用途
JP6637725B2 (ja) * 2015-10-28 2020-01-29 ビオフェルミン製薬株式会社 ウイルス感染症の予防及び／又は治療剤
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA45287A (fr) 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PT3313423T (pt) 2016-03-04 2019-07-10 4D Pharma Plc Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
KR102548553B1 (ko) * 2016-04-14 2023-06-27 듀폰 뉴트리션 바이오사이언시즈 에이피에스 제지방 체중을 증가시키기 위한 비피더스균
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN106579414A (zh) * 2016-12-26 2017-04-26 北京康比特体育科技股份有限公司 一种缓解运动性腹泻的组合物
CN106834187B (zh) * 2017-03-06 2020-08-25 江南大学 一种两歧双歧杆菌及其用途
WO2018165563A1 (en) * 2017-03-09 2018-09-13 The Clorox Company Probiotic capsule and methods of preparing the same
JP2018177703A (ja) * 2017-04-14 2018-11-15 株式会社明治 Ｔｏｌｌ様受容体２活性化用組成物
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
RS63393B1 (sr) 2017-06-14 2022-08-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
JP6840272B2 (ja) 2017-06-14 2021-03-10 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
EP4154722A1 (en) * 2018-01-29 2023-03-29 PrecisionBiotics Group Limited A combination product for prophylaxis and treatment of irritable bowel syndrome
KR102023700B1 (ko) * 2018-01-31 2019-09-20 주식회사 비피도 비피도박테리움을 함유한 류마티스관절염 개선용, 치료용 또는 예방용 조성물
JP7539163B2 (ja) * 2018-06-22 2024-08-23 シンフォーミュラス・ゲーエムベーハー ビフィドバクテリウム・ビフィダム非生菌及びその使用
ES2940808T3 (es) * 2019-01-16 2023-05-11 Nutricia Nv Preparado fermentado con oligosacáridos no digeribles para su uso en infecciones inducidas por rotavirus
IT201900011193A1 (it) * 2019-07-08 2021-01-08 Sofar Spa Ceppo di batteri Bifidobacterium bifidum, sue composizioni e relativi usi
BR112022004032A2 (pt) * 2019-09-05 2022-05-24 Superbrewed Food Inc Composições probióticas mixotróficas e usos das mesmas no tratamento de distensão abdominal
IT201900016811A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
CN112870233B (zh) * 2019-11-29 2024-08-23 伊利伊诺科技(上海)有限责任公司 包含乳双歧杆菌与母乳低聚糖的组合物及其应用
CN111110704B (zh) * 2020-02-14 2023-03-28 上海城建职业学院 一种益生菌菌剂、滴剂及其制备方法和应用
CN111743998A (zh) * 2020-06-04 2020-10-09 中通美雅生命健康(深圳)有限公司 用于辅助治疗肠炎组合物及其制备方法
RU2735717C1 (ru) * 2020-06-15 2020-11-06 Общество с ограниченной ответственностью "АВАН" Штамм Bifidobacterium bifidum, используемый в качестве пробиотика
CA3193257A1 (en) * 2020-09-23 2022-03-31 Dong Hyun Kim Novel lactic acid bacteria and use thereof
CN113943682B (zh) * 2020-11-12 2023-07-04 江南大学 缓解便秘的长双歧杆菌长亚种及其制备的发酵食品与益生菌制剂
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103634A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Improved use of cannabinoids in the treatment of epilepsy
CN113025526B (zh) * 2021-03-24 2022-09-27 江南大学 一株减少结肠病理损伤且具有缓解便秘作用的两歧双歧杆菌
CN112980734B (zh) * 2021-03-24 2022-07-22 江南大学 一株缓解便秘并调节肠道菌群紊乱的两歧双歧杆菌及其应用
CN113234619B (zh) * 2021-04-10 2022-07-05 江南大学 一株两歧双歧杆菌及其在缓解肠道损伤中的应用
CN116286439A (zh) * 2022-07-13 2023-06-23 四川大学 一株婴幼儿肠道来源的两歧双歧杆菌及应用
CN116004416B (zh) * 2022-07-13 2024-05-10 四川大学 婴幼儿肠道来源的两歧双歧杆菌的应用
CN115838662A (zh) * 2022-11-02 2023-03-24 江南大学 一株具有缓解克罗恩病潜力的两歧双歧杆菌
WO2024193633A1 (zh) * 2023-03-21 2024-09-26 四川厌氧生物科技有限责任公司 一种益生菌及其应用
CN118044616A (zh) * 2023-09-05 2024-05-17 厦门大学 一种合生元及其用途
WO2025059424A1 (en) * 2023-09-15 2025-03-20 Biohm Health Inc. Pro-biotic compositions and methods for treatment of stress
CN118879582B (zh) * 2024-09-19 2025-03-25 微康益生菌(苏州)股份有限公司 一种细胞完整、分散均匀、稳定性强的后生元制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
RU2152993C1 (ru) * 1999-11-30 2000-07-20 Государственный научный центр РФ Институт медико-биологических проблем Штамм bifidobacterium bifidum вкпм ас-1578, используемый для приготовления бактериальных препаратов и продуктов питания
RU2184146C1 (ru) * 2001-01-29 2002-06-27 Закрытое акционерное общество "Партнер" Штамм bifidobacterium bifidum 45 вкпм ас-1621, используемый для приготовления бактериальных препаратов и продуктов питания
EP1644482B2 (en) * 2003-06-30 2014-10-01 Clasado Inc. Novel galactooligosaccharide composition and the preparation thereof
JP4709838B2 (ja) * 2004-08-05 2011-06-29 アニドラル エス．アール．エル． 葉酸産生ビフィドバクテリウム菌株、製剤およびこれらの用途
BRPI0611492B1 (pt) * 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
CN100490826C (zh) * 2005-07-05 2009-05-27 广州市微生物研究所 多联活性双歧杆菌产品的制备方法
AU2006270824B2 (en) * 2005-07-21 2010-09-02 Kabushiki Kaisha Yakult Honsha Novel bacterium belonging to the genus bifidobacterium and utilization of the same
US9084434B2 (en) * 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
WO2008119012A2 (en) * 2007-03-27 2008-10-02 The Procter & Gamble Company Methods and kits for administering probiotics
DK2270133T3 (en) * 2008-04-22 2015-09-07 Corporación Alimentaria Peñasanta Capsa Method of obtaining a new strain of Bifidobacterium bidifum with effect against infection with Helicobacter pylori
RU2010143460A (ru) * 2008-05-01 2012-06-10 Дзе Проктер Энд Гэмбл Компани (US) Способы и наборы для терапии восстановительных состояний кишечника
EP2293677B1 (en) * 2008-06-13 2017-11-15 N.V. Nutricia Nutritional composition for infants delivered via caesarean section

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D1 : GUGLIELMETTI ET AL: "Implication of an outer surface lipoprotein in adhesion of Bifidobacterium bifdum to Caco-2 cells". Applied and Environmental Microbiology, 2008, vol. 74, no. 15, pages 4695-4702 *
D2 : GUGLIELMETTI ET AL: "Study of the adhesion of Bifidobacterium MIMBb75 to human intestinal cell lines". Current Microbiology, 2009, vol. 59, no. 2, pages 167-172 *

Also Published As

Publication number Publication date
EP2481299A1 (en) 2012-08-01
EP2481299B1 (en) 2016-12-07
HUE033189T2 (en) 2017-11-28
PL2481299T3 (pl) 2017-09-29
US9408879B2 (en) 2016-08-09
BR112013019258A2 (pt) 2016-10-11
PT2481299T (pt) 2017-03-08
BR112013019258A8 (pt) 2017-09-19
JP5956467B2 (ja) 2016-07-27
HRP20161792T1 (hr) 2017-03-10
WO2012104226A1 (en) 2012-08-09
CN103476273A (zh) 2013-12-25
RU2013137404A (ru) 2015-03-10
DK2481299T3 (en) 2017-02-06
NZ613544A (en) 2014-10-31
US20140056852A1 (en) 2014-02-27
CA2825980A1 (en) 2012-08-09
JP2014505065A (ja) 2014-02-27
CA2825980C (en) 2017-10-24
BR112013019258B1 (pt) 2021-09-08
ES2610908T3 (es) 2017-05-04
RU2603285C2 (ru) 2016-11-27

Similar Documents

Publication Publication Date Title
AU2012213576B2 (en) Bifidobacterium bifidum strains for application in gastrointestinal diseases
AU2012213576A1 (en) Bifidobacterium bifidum strains for application in gastrointestinal diseases
Patel et al. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics
BRPI0616962A2 (pt) uso de lactobacillus para o tratamento de doenças autoimunes
JP2002534113A (ja) 炎症性疾患治療におけるビフィドバクテリウム（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ）
MX2013006460A (es) Bifidobacterium cect 7765 y su uso en la prevencion y/o tratamiento del sobrepeso, la obesidad y patologias asociadas.
CN101998834B (zh) 用于缓解胃肠道病症相关症状的益生菌
CN112218646A (zh) 一种组合物及其应用
Marx Immunoprotective effects of probiotics in the elderly
JP2008502606A (ja) 乳酸菌及び下痢の予防におけるそれらの使用
WO2019227414A1 (zh) 一种组合物及其应用
Arora et al. Therapeutic potential of probiotics: A ray of hope or nightmare?
JP7539163B2 (ja) ビフィドバクテリウム・ビフィダム非生菌及びその使用
US20220193155A1 (en) Microbial compositions and methods for greater tolerability and prolonged shelf life
NZ613544B2 (en) Bifidobacterium bifidum strains for application in gastrointestinal diseases
RU2735717C1 (ru) Штамм Bifidobacterium bifidum, используемый в качестве пробиотика
Ringel What Are Probiotics and Do They Work in IBS?
Thayumanavan et al. Probiotics in gastroenterology
Lee et al. Probiotics in health and disease
US20190091270A1 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
Eseceli Pro-/Anti-Inflammatory Food Supplements: Probiotics and Prebiotics
Varshney An analysis of probiotics
Renwick et al. Manipulating the gut microbiota
WO2025047884A1 (ja) 細菌、組成物及び組成物の製造方法
DO THEY WORK WHAT ARE PROBIOTICS AND

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DR. FISCHER GESUNDHEITSPRODUKTE GMBH

Free format text: FORMER APPLICANT(S): NATURWOHL PHARMA GMBH

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SYNFORMULAS GMBH

Free format text: FORMER OWNER(S): DR. FISCHER GESUNDHEITSPRODUKTE GMBH